{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T20:46:08Z","timestamp":1778532368191,"version":"3.51.4"},"reference-count":16,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jfo.2025.104516","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T08:13:55Z","timestamp":1744618435000},"page":"104516","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Intravitreal injection of faricimab to treat macular and retinovascular diseases in Nigerians: Early real-world experience"],"prefix":"10.1016","volume":"48","author":[{"given":"O.N.","family":"Okonkwo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.O.","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Ajiboye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.Z.","family":"Onunwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Oyekunle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfo.2025.104516_bib0085","doi-asserted-by":"crossref","first-page":"327","DOI":"10.4103\/1119-3077.86778","article-title":"Age-related macular degeneration in Onitsham Nigeria","volume":"14","author":"Nwosu","year":"2011","journal-title":"Niger J Clin Pract"},{"key":"10.1016\/j.jfo.2025.104516_bib0090","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4103\/meajo.meajo_511_20","article-title":"Burden and presentation of age-related macular degeneration among Nigerians","volume":"25","author":"Okonkwo","year":"2021","journal-title":"Middle East Afr J Ophthalmol"},{"key":"10.1016\/j.jfo.2025.104516_bib0095","doi-asserted-by":"crossref","first-page":"679","DOI":"10.2147\/OPTH.S226494","article-title":"Profile, visual presentation and burden of retinal diseases seen in ophthalmic clinics in sub-saharan africa","volume":"14","author":"Nkanga","year":"2020","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jfo.2025.104516_bib0100","doi-asserted-by":"crossref","unstructured":"Okonkwo ON, Hassan AO, Akanbi T, et al. Polypoidal choroidal vasculopathy versus neovascular age related macular degeneration: A comparison of demographics, clinical presentation, and treatment outcomes in Nigerians. JFO Open Ophthalmol; 7. Epub ahead of print 2024. DOI: https:\/\/doi.org\/10.1016\/j.jfop.2024.100118.","DOI":"10.1016\/j.jfop.2024.100118"},{"key":"10.1016\/j.jfo.2025.104516_bib0105","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s10792-016-0391-4","article-title":"A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration","volume":"37","author":"Park","year":"2017","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.jfo.2025.104516_bib0110","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/IAE.0000000000001493","article-title":"Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab","volume":"37","author":"Avery","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.jfo.2025.104516_bib0115","first-page":"5397","article-title":"Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis","volume":"9","author":"Ba","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.jfo.2025.104516_bib0120","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ajo.2022.01.004","article-title":"KESTREL and KITE: 52-week results from two phase III pivotal trials of brolucizumab for diabetic macular edema","volume":"238","author":"Brown","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jfo.2025.104516_bib0125","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: phase 3, multicenter, randomizedm double-masked trials of brolucizumab for neovascular age-related macular degeneration","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jfo.2025.104516_bib0130","first-page":"1","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials","volume":"6736","author":"Heier","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jfo.2025.104516_bib0135","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","article-title":"Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials","volume":"399","author":"Wykoff","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jfo.2025.104516_bib0140","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s40123-022-00471-5","article-title":"Treatment outcome of wet age-related macular degeneration management in Thailand: a retrospective real-world study (TOWER Study)","volume":"11","author":"Thoongsuwan","year":"2022","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.jfo.2025.104516_bib0145","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1038\/s41433-023-02553-5","article-title":"The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study\u20136 month results","volume":"37","author":"Khanani","year":"2023","journal-title":"Eye"},{"key":"10.1016\/j.jfo.2025.104516_bib0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40942-024-00525-9","article-title":"Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME","volume":"10","author":"Penha","year":"2024","journal-title":"Int J Retin Vitr"},{"key":"10.1016\/j.jfo.2025.104516_bib0155","doi-asserted-by":"crossref","unstructured":"Bloom J, Madani R, Haidar AJ, et al. Faricimab Treatment of Polypoidal Choroidal Vasculopathy Resistant to Intravitreal Ranibizumab Injections and Ranibizumab Port Delivery (Susvimo). J Vitreoretin Dis; 0. Epub ahead of print 22 August 2024. DOI: 10.1177\/24741264241271739.","DOI":"10.1177\/24741264241271739"},{"key":"10.1016\/j.jfo.2025.104516_bib0160","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.ophtha.2024.01.029","article-title":"Efficacy and safety of faricimab for macular edema due to retinal vein occlusion: 24-week results from the BALATON and COMINO Trials","volume":"131","author":"Tadayoni","year":"2024","journal-title":"Ophthalmology"}],"container-title":["Journal Fran\u00e7ais d'Ophtalmologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551225000981?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0181551225000981?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T13:07:03Z","timestamp":1762261623000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0181551225000981"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0181551225000981"],"URL":"https:\/\/doi.org\/10.1016\/j.jfo.2025.104516","relation":{},"ISSN":["0181-5512"],"issn-type":[{"value":"0181-5512","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravitreal injection of faricimab to treat macular and retinovascular diseases in Nigerians: Early real-world experience","name":"articletitle","label":"Article Title"},{"value":"Journal Fran\u00e7ais d'Ophtalmologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfo.2025.104516","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104516"}}